In solid tumors and lymphomas, the neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor. The aim of our study was to validate the originally reported N/L ratio cut-point of 3.5 in patients with diffuse large B-cell lymphoma (DLBCL) registered in an Italian real-life database. The prognostic role of the N/L ratio at diagnosis on event-free survival (EFS) and overall survival (OS) was assessed in 505 patients with DLBCL. Patients with an N/L ratio <3.5 (n = 249) had a 4-year EFS probability of 76% and OS probability of 86%, significantly higher than the 4 year EFS rate of 48% and OS rate of 64% in patients with N/L ratio ≥3.5 (n = 256, both p<.0001). The N/L ratio was an independent prognostic factor in the multivariate analysis including the IPI score, and could separate patients with a low/intermediate risk IPI (IPI <3).
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma. a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) / Annibali, O.; Hohaus, S.; Marchesi, F.; Cantonetti, M.; Di Rocco, A.; Tomarchio, V.; Di Napoli, A.; Pelliccia, S.; Battistini, R.; Anticoli Borza, P.; Abruzzese, E.; Cenfra, N.; Andriani, A.; Tesei, C.; Alma, E.; Palombi, F.; Pupo, L.; Petrucci, L.; Becilli, M.; Maiolo, E.; Bellesi, S.; Cuccaro, A.; D'Alo, F.; Cox, M. C.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - Jul 1(2019), pp. 1-9. [10.1080/10428194.2019.1633628]
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma. a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)
Marchesi F.;CANTONETTI, MONICA;Di Rocco A.;Di Napoli A.;Pelliccia S.;Cenfra N.;Tesei, Cristiano;Alma E.;Palombi F.;Petrucci L.;BELLESI, SERENA;Cuccaro A.;
2019
Abstract
In solid tumors and lymphomas, the neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor. The aim of our study was to validate the originally reported N/L ratio cut-point of 3.5 in patients with diffuse large B-cell lymphoma (DLBCL) registered in an Italian real-life database. The prognostic role of the N/L ratio at diagnosis on event-free survival (EFS) and overall survival (OS) was assessed in 505 patients with DLBCL. Patients with an N/L ratio <3.5 (n = 249) had a 4-year EFS probability of 76% and OS probability of 86%, significantly higher than the 4 year EFS rate of 48% and OS rate of 64% in patients with N/L ratio ≥3.5 (n = 256, both p<.0001). The N/L ratio was an independent prognostic factor in the multivariate analysis including the IPI score, and could separate patients with a low/intermediate risk IPI (IPI <3).| File | Dimensione | Formato | |
|---|---|---|---|
|
Annibali_neutrophil/lymphocyte_2019.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.27 MB
Formato
Adobe PDF
|
1.27 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
